芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

zentiva k.s. - azacitidine - injektiokuiva-aine, suspensiota varten - 25 mg/ml - atsasitidiini

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - abacavir - tabletti, kalvopäällysteinen - 300 mg - abakaviiri

欧盟 - 芬兰文 - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressantit - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

bayer ag -

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

novartis consumer health sa - dimetindeni maleas - depottabletti - 2.5 mg - dimetindeeni

欧盟 - 芬兰文 - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemaattinen - immunosuppressantit - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - sytomegalovirusinfektiot - antiviraalit systeemiseen käyttöön - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). on otettava huomioon viralliset ohjeet asianmukaista käyttöä antiviraalisten aineiden.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellituksen hoito.